Bristol Myers Squibb is a global biopharmaceutical company headquartered in New York City, United States. It was founded in 1887 by William McLaren Bristol and John Ripley Myers. The company has a rich history of developing innovative medicines to address unmet medical needs.

Bristol Myers Squibb's headquarters is located in the iconic building at 430 E. 29th Street in New York City. The company utilizes this location as a hub for its corporate functions, including executive management, finance, legal, and human resources.

The company specializes in the development and commercialization of prescription drugs across various therapeutic areas, including oncology, cardiovascular diseases, immunoscience, fibrosis, and more. Some of its key products include Opdivo, a cancer immunotherapy drug, Eliquis, an anticoagulant, and Orencia, a treatment for rheumatoid arthritis. With a global presence, Bristol Myers Squibb operates in over 60 countries worldwide.

The company has established a number of noteworthy subsidiaries, joint ventures, and partnerships. Celgene, acquired by Bristol Myers Squibb in 2019, is one such significant subsidiary, known for its expertise in oncology and autoimmune diseases. Joint ventures, such as the one with Pfizer for the development and commercialization of Eliquis, have also contributed to the company's success.

In terms of market position, Bristol Myers Squibb is considered one of the leading biopharmaceutical companies globally. It has achieved significant global sales, consistently ranking among the top pharmaceutical companies in revenue. The company faces competition from other major players in the industry, such as Pfizer, Merck, and Novartis.

Over the years, Bristol Myers Squibb has undergone major changes in its strategy and product lineup. Notably, the acquisition of Celgene has significantly expanded the company's portfolio and strengthened its position in the oncology market. This strategic move has allowed Bristol Myers Squibb to offer a wider range of treatment options to patients.

As of the latest updates, Bristol Myers Squibb continues to focus on developing innovative medicines and therapies. The company remains committed to its mission of discover, develop, and deliver transformative medicines for patients. It continues to invest in research and development to address unmet medical needs and bring new treatments to market.

In conclusion, Bristol Myers Squibb is a prominent biopharmaceutical company headquartered in the United States, known for its innovative medicines across therapeutic areas. With its global operations, noteworthy subsidiaries, and strategic partnerships, the company has established a strong market position. The recent acquisition of Celgene and ongoing research and development efforts further highlight its commitment to growth and providing groundbreaking treatments to patients worldwide